Sanofi, RadioMedix, and Orano Med sign $110M deal for advanced radioligand cancer therapy

Sanofi, RadioMedix, and Orano Med have signed an exclusive licensing agreement to develop AlphaMedixTM, a cutting-edge radioligand treatment for rare cancers.

Sanofi will be responsible for the global commercialization of AlphaMedixTM, while Orano Med will manage the manufacturing through a developing global platform. RadioMedix and Orano Med will receive an initial payment of $110 million (€100 million), with the possibility of additional payments based on sales milestones and tiered royalties.

AlphaMedixTM is in the late stages of clinical trials and is being tested for treating neuroendocrine tumors (NETs), a rare type of cancer. This radioligand therapy uses lead-212 (212Pb) to deliver targeted radiation to cancer cells. Recently, it received Breakthrough Therapy Designation from the U.S. FDA for its potential in treating patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have not previously undergone peptide-receptor radionuclide therapy. Clinical trials have demonstrated promising results, showing a significant tumor response rate, which positions the therapy as a potential advancement in cancer treatment.

Neuroendocrine tumors are rare and primarily affect the gastrointestinal system but can also occur in other body parts. Despite their rarity, the incidence of NETs is increasing globally.